Cure & Advancements/January 21, 2026/2 min read

How the ELSA Study Helped One UK Family Access Teplizumab Before Type 1 Diabetes Developed

Imogen was identified as having early-stage type 1 diabetes through a research study, then became only the second child in the UK to receive teplizumab—a drug designed to delay the onset of the condition. Her mother shares what this opportunity has meant for their family.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

The ELSA study can detect type 1 diabetes in its earliest stages, before symptoms appear
Teplizumab is designed to slow the progression of type 1 diabetes and potentially delay the need for insulin therapy
Some people may access promising new treatments early through managed access programmes, though these are typically available to small numbers of eligible people
Early detection through research can open doors to interventions that were not previously available to patients

A Diagnosis Before Symptoms

When 12-year-old Imogen took part in the ELSA study, researchers discovered something significant: she was in the early stages of type 1 diabetes, despite having no symptoms. For her mother Amy, a mental health practitioner from the West Midlands who lives with type 1 diabetes herself, this finding offered something unexpected—a chance to act before the condition fully developed.

Because Amy has type 1 diabetes, Imogen was at higher risk of developing it too. The ELSA study's ability to detect the disease at this earliest stage meant the family had information and options they wouldn't normally have had.

Access to Teplizumab Through a Managed Access Programme

Following her diagnosis through ELSA, Imogen became the second child in the UK to access teplizumab—an immunotherapy drug designed to slow the progression of type 1 diabetes. She was able to receive the treatment through a managed access programme run by the drug's manufacturer, which allows small numbers of carefully selected people to try promising new treatments before they become more widely available.

These programmes are typically limited in scope, making access selective and based on specific eligibility criteria. Imogen's participation in ELSA and her early-stage diagnosis qualified her for this opportunity.

What Teplizumab Aims to Do

Teplizumab is designed to slow how quickly type 1 diabetes develops. The goal is to give patients extra time—potentially years—before insulin therapy becomes necessary. For families like Imogen's, this delay can mean more time to prepare, adjust, and plan for life with diabetes.

It's important to note that teplizumab is not a cure. Rather, it is intended to delay the onset of the condition in people who are identified early enough to receive it.

The Hope of Early Detection

For Amy, participating in research and accessing teplizumab has offered something precious: hope and extra time. Knowing that Imogen is in the early stages of type 1 diabetes, rather than facing sudden symptoms, allows the family to prepare emotionally and practically.

Stories like Imogen's highlight why early detection studies matter—they can identify people at the right moment to potentially benefit from new treatments that simply weren't available to previous generations.

Evidence label

Origin: diabetes.org.uk (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.